Home › Companies › XNCR

Xencor

XNCR Rare disease Lead: Approved 1 Biotech Distilled article ↓

Hematology Immunology Infectious Disease Neurology Oncology Renal Protein

Most recent annual filing: 2026-02-25

Pipeline (30 active programs)

XmAb819

Protein Target: ENPP3, CD3

XmAb541

Protein Target: CLDN6, CD3

Ovarian Cancer Phase 1

XmAb808

Protein Target: B7-H3, CD28

Solid Tumors Phase 1

XmAb942

Protein Target: TL1A

plamotamab

Protein Target: CD20, CD3

Rheumatoid Arthritis Phase 1

XmAb657

Protein Target: CD19, CD3

Idiopathic Inflammatory Myopathies Phase 1

XmAb412

Protein Target: TL1A, IL23p19

xaluritamig

Protein Target: STEAP1, CD3

Metastatic Castration-Resistant Prostate Cancer Phase 3 Amgen

obexelimab

Protein Target: CD19

Relapsing Multiple Sclerosis Phase 2 Zenas
Immunoglobulin G4-Related Disease NDA Submitted Zenas
Systemic Lupus Erythematosus Phase 2 Zenas

ASP2138

Protein Target: CLDN18.2, CD3

Gastric Cancer Phase 1 Astellas
Gastroesophageal Junction Cancer Phase 1 Astellas
Pancreatic Cancer Phase 1 Astellas

JNJ-9401

Protein Target: PSMA, CD28

Metastatic Castration-Resistant Prostate Cancer Phase 1 Janssen Biotech

JNJ-1493

Protein Target: CD20, CD28

B-Cell Lymphoma Phase 1 Janssen Biotech

tobevibart

Chronic Hepatitis Delta Phase 3 Vir Biotechnology

zaltenibart

Protein Target: MASP-3

Paroxysmal Nocturnal Hemoglobinuria Phase 2 Novo Nordisk

teropavimab

HIV Infection Phase 2 Gilead Sciences

zinlirvimab

HIV Infection Phase 2 Gilead Sciences

Monjuvi

tafasitamab

Protein Target: CD19

Diffuse Large B-Cell Lymphoma Approved Incyte
Follicular Lymphoma Approved Incyte

Ultomiris

Paroxysmal Nocturnal Hemoglobinuria Approved Alexion
Atypical Hemolytic Uremic Syndrome Approved Alexion
Generalized Myasthenia Gravis Approved Alexion
Neuromyelitis Optica Spectrum Disorder Approved Alexion

Technology platforms

XmAb Bispecific Fc Domain

Modular Fc engineering platform enabling multispecific antibody formats including 2+1 bispecific, CD3 T-cell engagers, CD28 co-stimulatory bispecifics, and trispecific formats. Applicable across oncology and autoimmune diseases.

Xtend Fc Domain

Engineered Fc domain designed to extend antibody half-life through FcRn receptor engagement on endothelial cells. Used in XmAb942, Ultomiris, tobevibart, and zaltenibart programs across IBD, PNH, and infectious disease.

Targets: FcRn

Discontinued (1)

vudalimab — Metastatic Castration-Resistant Prostate Cancer · Development paused (Xencor, 2026 10-K)

Biotech Distilled coverage (1)

2026-06-27 Xencor, Inc. (XNCR) — Scientific Deep Dive for XmAb819, XmAb942 and the XmAb Pipeline

Articles open on Substack. Some deep dives are subscriber-only.